Schizophrenia/Psychosis

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Serum drug levels provide crucial insights for optimizing psychiatric treatment, enhancing patient outcomes in cases of schizophrenia and OCD.

Extreme heat poses serious health risks, especially for vulnerable populations. Learn essential tips to help patients stay safe during heat waves and protect their well-being.

Learn more about effective strategies for managing obesity and metabolic dysfunction in schizophrenia, focusing on dietary interventions and pharmacological treatments.

Panelists discuss how real-world experience with xanomeline/trospium chloride shows efficacy across all 3 symptom domains with manageable gastrointestinal adverse effects that typically resolve within 2 weeks, requiring slow titration and patient education about empty stomach dosing.

Panelists discuss how xanomeline/trospium chloride represents a first-in-class medication with a novel muscarinic mechanism that addresses positive, negative, and cognitive symptoms while avoiding typical antipsychotic adverse effects such as movement disorders and prolactin elevation.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

Discover groundbreaking schizophrenia treatment with xanomeline-trospium, targeting cholinergic pathways for improved symptoms and fewer side effects.

Discover promising new treatments for schizophrenia, including NBI-1117568 and CPL’36, showcasing significant symptom improvements and safety profiles.

Johnson & Johnson has submitted an sNDA for Caplyta, showcasing significant relapse prevention in schizophrenia.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Innovative digital therapeutics like CT-155 are transforming mental health treatment, targeting negative symptoms of schizophrenia and enhancing depression care. Check out this conversation with Shaheen Lakhan, MD, PhD.

It is critical to recognize the early signs of schizophrenia and provide timely intervention to prevent full-blown psychosis in adolescents.

The FDA's removal of clozapine REMS enhances access to treatment, while new educational initiatives empower clinicians to improve patient care.

Learn more about how to best assess and treat tardive dyskinesia.

Recent research reveals dopamine partial agonists significantly reduce somnolence in major depressive disorder and schizophrenia compared with D2 receptor antagonists.

Neurocrine Biosciences reveals promising phase 2 results for NBI-1117568, a novel treatment for schizophrenia, showing significant symptom improvement over placebo.

Learn more about the critical link between early adversity and psychosis, and the need for targeted interventions and preventive measures.

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

Early intervention in schizophrenia enhances recovery, reduces symptoms, and improves quality of life through coordinated specialty care programs across the US.

In this Special Report, explore groundbreaking insights on schizophrenia treatment, early intervention strategies, and the impact of childhood trauma on psychosis.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.